Recently, a novel scoring system that includes age, male sex, albumin-bilirubin, and platelets (aMAP) has been proposed, and its performance in assessing the 5-year HCC risk has been validated in several cohorts with different etiologies and ethnicities (16), but its performance for late HCC after a longer period of treatment warrants further research. This evidence concerns the gene ALB and hepatocellular carcinoma.